Oxford BioDynamics, a UK biotech focused on the discovery and development of biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitch, announces that Dr Jon Burrows has been appointed as group chief executive, effective 23 March 2020. 16 March 2020
German newspaper Welt am Sonntag over the weekend said that US President Donald Trump “had offered funds” to entice German mRNA-based drug specialist CureVac to move its recently started COVID-19 R&D work to the USA, and the German government was now “making counter-offers to tempt it to stay.” 16 March 2020
Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, today announced that Lisa Johnson-Pratt has joined the company as senior vice president of new product strategy. 11 March 2020
Germany’s Stada Arzneimittel says it is now the largest foreign investor in the Russian pharmaceutical industry, following the completion of a $660 million transaction for a Russian brand portfolio from Japan’s Takeda. 5 March 2020
Successful Danish biotech company Genmab (Nasdaq: GMAB) said late Friday that its chairman, Mats Pettersson, has decided to step down from the post on March 26, when his election period expires. 24 February 2020
H3 Biomedicine, the USA-based precision medicine subsidiary of Japanese drugmaker Eisai, has named industry veteran Antonio Gualberto its chief medical officer (CMO). 20 February 2020
US biotech major Gilead Sciences announced today that Michael Quigley has joined the company as senior vice president, Research Biology, bringing to the role deep experience in oncology and immuno-oncology biology. 19 February 2020
The UK’s Healx, an AI-powered and patient-inspired technology company, today announced the appointment of Dr Anthony Hall as chief medical officer (CMO). 4 February 2020
German drugmaker Stada Arzneimittel has appointed Wolfgang Ollig as group chief financial officer (CFO) with effect from February 1, 2020. 31 January 2020
A better-than-forecast financial results statement has sent Eli Lilly stock climbing nearly 1.5% in pre-market trading. Shares were already up 0.47% after strong trading on Wednesday. 30 January 2020
Late Thursday, French metabolic diseases biotech company Poxel announced the appointment of pharma industry veteran David Moller as chief scientific officer (CSO). 24 January 2020
Chinese biotech start-up Antengene recently hired two former high-profile managers from its funding partner Celgene, now a Bristol-Myers Squibb (NYSE: BMY) company. In a recent meeting in Shanghai, where Antengene is based, founder and chief executive Jay Mei spoke with The Pharma Letter about the hires and his vision for his company. 16 January 2020
Having just announced the first launch of its new gene therapy Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene), in Germany, US gene therapy company bluebird bio has appointed former Celgene executive Nicola Heffron to head up its European operations, based in Zug, Switzerland. 16 January 2020
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024